Belimumab for the treatment of refractory systemic lupus erythematosus: real-life experience in the first year of use in 18 Italian patients

Isr Med Assoc J. 2014 Oct;16(10):651-3.
No abstract available

Publication types

  • Clinical Trial

MeSH terms

  • Administration, Intravenous
  • Adult
  • Antibodies, Antinuclear / blood
  • Antibodies, Antiphospholipid / blood
  • Antibodies, Monoclonal, Humanized* / administration & dosage
  • Antibodies, Monoclonal, Humanized* / adverse effects
  • Dose-Response Relationship, Drug
  • Drug Monitoring
  • Drug Therapy, Combination / methods
  • Female
  • Follow-Up Studies
  • Glucocorticoids* / administration & dosage
  • Glucocorticoids* / adverse effects
  • Humans
  • Immunosuppressive Agents / administration & dosage
  • Immunosuppressive Agents / adverse effects
  • Italy
  • Lupus Erythematosus, Systemic* / blood
  • Lupus Erythematosus, Systemic* / diagnosis
  • Lupus Erythematosus, Systemic* / drug therapy
  • Lupus Erythematosus, Systemic* / physiopathology
  • Patient Acuity
  • Treatment Outcome

Substances

  • Antibodies, Antinuclear
  • Antibodies, Antiphospholipid
  • Antibodies, Monoclonal, Humanized
  • Glucocorticoids
  • Immunosuppressive Agents
  • belimumab